A widely prescribed monoclonal antibody for patients with wet age-related macular degeneration, Lucentis (ranibizumab), has been approved in the US for a new indication – diabetic retinopathy in patients with diabetic macular oedema. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
